Kornimate/medical-research-clean huggingface dataset:
efficacy of intralesional injection of pentoxifylline, platelet-rich plasma, and combined pentoxifylline with platelet-rich plasma in patients with atrophic acne scars

Conditions: Atrophic Acne Scar

Summary: platelet-rich plasma (prp) is an acne vulgaris is a common chronic inflammatory skin disorder. it is the eighth most prevalent disease worldwide with a prevalence of 9.4%. acne scar is one of the most persistent complications of acne, causes marked psychological stress to the patient . the process of acne scar formation can be broadly divided into two stages: increased tissue formation and loss or damage of tissue, corresponding to keloid or hypertrophic scar and atrophic scar, respectively. the ultimate severity of acne scars is correlated with acne grade and the delay in treatment of active disease. the atrophic scars include three subtypes: icepick or v-shaped, rolling or m-shaped, and boxcar or u-shaped scars. among atrophic scars, the ice pick type represents 60%-70%; the boxcar type represents 20%-30%; and the rolling type represents 15%-25% (salameh and shumaker, 2022). according to the qualitative scarring grading system, a macular acne scar type also exists, which clinically shows erythematous, hyperpigmented, or hypopigmented flat marks. autologous blood product containing high concentrations of platelets in a small volume of plasma. prp has been utilized in the treatment of orthopedic, musculoskeletal, and maxillofacial conditions for many years, it has only recently gained popularity in dermatology. prp contains various growth factors, including platelet-derived growth factor (pdgf), transforming growth factor (tfg), vascular endothelial growth factor (vegf), and insulin-like growth factor (igf). these growth factors stimulate tissue remodeling and are associated with enhanced healing through the attraction of macrophages, upregulation of collagen synthesis, and promotion of tissue regeneration. moreover, platelet-derived growth factor (pdgf) was shown to promote wound healing, angiogenesis, and tissue remodeling.


Eligibility criteria:
inclusion criteria: * aged \> 18 years old. * both sexes. * all types of atrophic acne scars exclusion criteria: * • pregnant or lactating women. * coagulation disorders or anemia. * skin infections. * patients with hormonal disturbance. * chronic disease e.g: diabetes, renal disease....etc. * refusal to participate.
a trial of same for treatment-resistant bipolar depression

Conditions: Bipolar Disorder; Depression; Bipolar Depression

Summary: s-adenosyl-l-methionine (same) is a dietary supplement with antidepressant properties. same's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants. the purpose of this study is to examine the effect of these properties on the mood of bipolar subjects with persistent major depression that has been unresponsive to standard pharmacotherapy.

depression in bipolar disorder is a significant source of disease-related debility; with bipolar individuals typically spending three fold as much time depressed as manic or hypomanic. clinicians treating bipolar disorder often struggle to provide relief from depressive symptoms that are more often treatment resistant than in unipolar depression. to complicate matters further, the risk/benefit ratio of currently available antidepressants is a source of debate within the field of psychiatry. s-adenosyl-l-methionine (same) is a dietary supplement with well-established antidepressant properties. same's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants. the purpose of this study is to examine the effect of these properties on the mood of bipolar subjects with persistent major depression that has been unresponsive to standard pharmacotherapy. an unusual aspect of the current study design is the schedule of same dosing. same tablets will be administered intermittently and in steadily increasing dosages. the purpose of this gradual and intermittent dosage titration is to lessen the risk of antidepressant-induced mania by seeking the minimum effective oral dose of same.

Eligibility criteria:
inclusion criteria: * bipolar disorder * depressed for 3-12 months * mood unresponsive to at least 2 treatments * currently on mood stabilizer at therapeutic doses exclusion criteria: * history of mania while on adequate mood stabilizer * rapid cycling bipolar disorder * previous use of same during current episode * unstable medical illness including parkinson's disease * methotrexate use * pregnancy * substance abuse/dependence

Keywords: same alternative treatments bipolar disorder depression bipolar depression treatment-resistant depression
radiofrequency ablation in treating patients with liver cancer (hepatocellular carcinoma)

Conditions: Carcinoma, Hepatocellular

Summary: this phase ii trial studies how effectively radiofrequency ablation prevents recurrence of hepatocellular carcinoma (hcc) in patients with easily removable tumors. radiofrequency ablation uses a high-frequency, electric current to kill tumor cells.


Eligibility criteria:
inclusion criteria: * histologically proven hcc or unambiguous radiologic findings consistent with hcc (\> 1 cm tumor with arterial hypervascularity and venous or delayed phase washout) in patients with underlying liver disease. * disease must be considered unresectable (as defined by protocol). * age between 18 and 69 (inclusive). * karnofsky performance status of ≥ 80% * normal organ and marrow function as defined below: * leukocytes ≥3,000/mcl * absolute neutrophil count ≥1,500/mcl * platelets \>100,000/mcl * total bilirubin \<2.0 mg/dl * ast(sgot)/alt(sgpt) ≤2.5 x institutional upper limit of normal * creatinine within normal institutional limits or * creatinine clearance ≥60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal * presence of ≤ 3 tumors, all of which are ≤ 3 cm in size. this will be determined preoperatively and confirmed by intraoperative ultrasound. * liver function of child-pugh class a or b * tumor(s) must be more than 2 cm away from of major biliary duct or major blood vessel defined as the main portal vein and its right and left primary branches and the first 1 cm of the secondary branches of the common hepatic duct and its right and left primary branches or the first 1 cm of its secondary branches. * able to understand and willing to sign a written informed consent document. exclusion criteria: * hepatic tumor(s) with satellite lesions. a satellite lesion is defined as a tumor which is within 2 cm of the tumor being assessed for treatment and which has a diameter of less than 33% of the diameter of the tumor being assessed for treatment. * evidence of metastatic/extrahepatic disease based on abdominal and chest ct performed within 4 weeks of the procedure. * extrahepatic disease upon laparoscopy performed at the time of rfa. if extrahepatic disease is discovered at this laparoscopy, rfa will not be performed, and the patient will be considered ineligible for this study and will be replaced. * pregnancy. all women of childbearing potential must have a negative pregnancy test prior to enrollment in the study. * significant portal hypertension based on evidence of esophageal varices or ascites. minimal portal hypertension or ascites will not be an exclusion criterion. * previous history of hcc or any other non-cutaneous malignancy. patients who are found to be ineligible due to intraoperative findings will be recorded as to the cause of ineligibility. they will not be counted as accrued patients. -inclusion of women and minorities both men and women and members of all races and ethnic groups are eligible for this trial.
aerobic exercise in early subacute stroke

Conditions: Stroke

Summary: the purpose of this study was to investigate the effects of early intensive aerobic exercise regarding aerobic capacity, gait and balance, health related quality of life and participation.


Eligibility criteria:
inclusion criteria: * ability to understand swedish language. * ability to walk 5 meters with or without the support of any means or person. * be able to get up on a cycle ergometer and cycle in their own chosen pace. * approval of medically responsible physician to conduct physical training in groups. exclusion criteria: * medical or neurological diseases that may affect the exercise execution. * patients for whom transportation to and from hospital can not be arranged during intervention period

Keywords: stroke exercise randomized trial quality of life
efficacy and safety of lcz696 compared to olmesartan in essential hypertensive patients not responsive to olmesartan

Conditions: Hypertension

Summary: this study will assess the efficacy and safety of lcz696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan


Eligibility criteria:
inclusion criteria: * patients with mild to moderate hypertension, untreated or currently taking antihypertensive therapy * treated patients (using antihypertensive drugs within 4 weeks prior to first visit) must have an office mssbp ≥ 145 mmhg and \< 180 mmhg after washout epoch and after 4 weeks run-in epoch * untreated patients (either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit) must have an offcie mssbp ≥ 150 mmhg and \< 180 mmhg at screening and 1 week after screening and must have an office mssbp ≥ 145 mmhg and \< 180 mmhg after 4 weeks run-in epoch * patients must successfully complete abpm and pass technical requirements to be qualified for randomization exclusion criteria: * malignant or severe hypertension (grade 3 of who classification; msdbp ≥110 mmhg and/or mssbp ≥ 180 mmhg) * history of angioedema, drug-related or otherwise * history or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, cushing's disease, pheochromocytoma, polycystic kidney disease (pkd), drug-induced hypertension * patients who previously entered a lcz696 study and had been randomized or enrolled to receive active drug treatment

Keywords: hypertension, lcz696, olmesartan
haploidentical stem cell transplantation and nk cell therapy in patients with high-risk solid tumors

Conditions: Neuroblastoma; Ewing Sarcoma; Rhabdomyosarcoma; Osteosarcoma; Soft Tissue Sarcoma

Summary: to evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation. to evaluate feasibility and efficacy of nk cell infusion after haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation.

haplosct following reduced-intensity conditioning (ric) regimen will be performed in patients with high-risk solid tumors. both parents will be evaluated for their kir genotype and phenotype and the one with the greatest degree of kir-l mismatch with the patient will be selected as the donor. in addition, ex-vivo expanded nk cells derived from the donor will then be administered after haplosct to increase the gvt effect. low-dose il-2 will be given after expanded nk cell infusion to enhance nk cell alloreactivity.

Eligibility criteria:
inclusion criteria: * age \< 21 years old * patients with high-risk solid tumors who failed prior hdct/autosct * patients with a suitable haploidentical donor * high-risk solid tumors include high-risk neuroblastoma, metastatic or relapsed ewing sarcoma, relapsed osteosarcoma, high-risk brain tumors, relapsed germ cell tumors, relapsed soft tissue sarcoma, relapsed rhabdomyosarcoma, and etc. * stable disease with salvage chemotherapy after relapse exclusion criteria: * organ dysfunction(nci common toxicity criteria grade \> 2) * progression of disease despite salvage chemotherapy

Keywords: haploidentical stem cell transplantation natural killer cell therapy pediatric solid tumor
a clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (ideglira) versus insulin glargine (iglar) as add-on therapy to sglt2i in subjects with type 2 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted globally. the aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (ideglira) versus insulin glargine (iglar) as add-on therapy to sglt2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: - male or female, age at least 18 years at the time of signing informed consent - subjects diagnosed (clinically) with type 2 diabetes mellitus - hba1c 7.0-11.0% \[53-97 mmol/mol\] (both inclusive) by central laboratory analysis - body mass index (bmi) equal to or above 20 kg/m\^2 and below 40 kg/m\^2 - insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as well as prior insulin treatment for gestational diabetes - a stable daily dose for at least 90 days prior to the day of screening of any sglt2i in monotherapy or in combination with metformin ± dpp4i ± pioglitazone. use of pioglitazone is not allowed in subjects treated with dapagliflozin exclusion criteria: - receipt of any investigational medicinal product within 90 days prior to screening - use of any oads (other than sglt2i in monotherapy or in combination with metformin or dpp4i or pioglitazone as described in the inclusion criteria) within 90 days prior to the day of screening - use of glucagon-like peptide-1 (glp-1) receptor agonist (e.g., exenatide or liraglutide) within 90 days prior to the day of screening - acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days prior to the day of the screening - subjects presently classified as being in nyha (new york heart association) class iii or iv1 - renal impairment estimated glomerular filtration rate 60 ml/min/1.73 m2 as per ckd-epi (chronic kidney disease epidemiology collaboration) - impaired liver function, defined as alt (alanine aminotransferase) equal to or above 2.5 times upper normal limit at screening - known or suspected hypersensitivity to trial product(s) or related products
efficacy and safety of radiofrequency versus hal- rar doppler in hemorrhoidal pathology

Conditions: Hemorrhoids

Summary: haemorrhoids are composed of tissue rich in blood vessels and are present in all individuals inside the anus (internal haemorrhoids) or under the skin of the anus (external haemorrhoids). haemorrhoidal disease (hd) occurs when haemorrhoids become troublesome and cause symptoms such as pain, bleeding, prolapse or oozing. in case of failure of medical treatment, instrumental procedures or extensive disease, surgical treatment can be considered. there are two classic surgical techniques. the first is the pedicle haemorrhoidectomy of the milligan and morgan type. the second classic surgical technique is the longo stapled anopexy. recently, less invasive surgical techniques such as arterial ligation (hal, with or without doppler) followed by recto-anal repair (rar for "recto anal repair") and sometimes associated with mucopexy, which allows the excess mucosa to be ligated and the muco-haemorrhoidal tissue to be fixed to the rectal wall, have developed. the use of radiofrequency current (rafaelo technique) in the treatment of haemorrhoidal disease is an innovative technique of haemorrhoidal thermocoagulation. it is a mini-invasive technique, which can be performed under sedation or short general anaesthesia (ga), with little pain, allowing a rapid return to normal life and a short time off work. although this technique is already used in other european countries: poland, germany, belgium, great britain (uk), there is now a polish, german, spanish and english study in the process of publication. there have been no studies in france to evaluate this new technique and assess its good tolerance, the duration of work stoppage, the improvement in quality of life and the evaluation of its effectiveness.


Eligibility criteria:
inclusion criteria: * male or female consulting for hemorrhoidal pathology (grade ii or iii) after failure of medico-instrumental treatments. * age ≥ 18 years and \< 75 years * mandatory affiliation to a health insurance system. * patient having been informed of the study and having given informed consent exclusion criteria: * patients with chronic inflammatory bowel disease * patients with suspected gastro-colic pathology * haematological diseases * anal fistulas * patients unable to discontinue anti-vitamin k or oral anticoagulants * associated anal fissure * external haemorrhoidal disease * pregnant or breastfeeding women * patients under legal protection
development of an intervention to enhance cancer pain management

Conditions: Other Cancer

Summary: this research study is being done to understand how patients with chronic cancer pain take their long-acting opioid medications, and to develop an intervention to enhance cancer pain management.

long-acting opioids are a common treatment for cancer pain. the purpose of this study is to develop a program for patients who are taking a prescribed long-acting opioid for their cancer pain. participants will be enrolled in this study at the massachusetts general hospital cancer center. this 14-week study involves completing a set of questionnaires at three different times during the study period. . during the study period, participants will use electronic pill caps to monitor their pain medication taking. they also will attend a series of three visits with one of the nurse practitioners on their care cancer team. the visits will focus on learning and practicing skills for managing cancer pain. the information that the investigators collect will help identify whether the sessions are feasible and useful to patients during the course of treatment for cancer pain. this trial will consist of two parts: part 1: this is a single-group prospective observational study. investigators will use quantitative and qualitative methods to examine rates, predictors and outcomes of adherence to la opioids over a period of approximately eight weeks. this information will be used to inform part 2 intervention development and testing. part 2: investigators will test the behavioral intervention in a non-randomized open pilot, over a period of approximately six weeks. intervention process data, psychosocial and medical data, and post-intervention feedback will be collected to assess feasibility and acceptability. in an iterative process, ongoing data from exit interviews and therapist experience will be used to modify the intervention protocol.

Eligibility criteria:
inclusion criteria: * age 21 or older * currently prescribed a long-acting (la) opioid for nociceptive cancer pain (extended release oxycodone, extended-release morphine, transdermal fentanyl patches, methadone tablets) * ability to comprehend study materials in english * eastern cooperative oncology group (ecog) performance status ≤ 2 * in charge of administering own pain medications * part 2 study only: within 4 months of current prescription of la opioid for nociceptive cancer pain exclusion criteria: * impaired cognition, active substance disorder, or other active, unstable mental health disorder * current long-acting opioid treatment for pre-existing condition * part 2 study only: prior enrollment in the part 1 study\*\*

Keywords: other cancer
a study of esomeprazole in children with autism

Conditions: Autism; Autism Spectrum Disorder

Summary: autism is a pervasive developmental disorder characterized by core deficits in social behavior and communication and the presence of repetitive/stereotyped behaviors. the objective of the study is to evaluate the efficacy of esomeprazole as a treatment for social communication deficits in children with autism spectrum disorder (asd). this prospective 12 week open-label study will invite 25 children with asd between the ages of 2 and 6 years of age to participate.


Eligibility criteria:
inclusion criteria: * outpatients 2 to 6 years of age; * males and females who are physically healthy; * diagnosis of autism spectrum disorder based on clinical evaluation and dsm-5 criteria, and confirmed using the autism diagnostic interview-revised, and the autism diagnostic observation schedule; * care provider who could reliably bring subject to clinic visits, could provide trustworthy ratings, and interacted with subject on a regular basis; * ability of subject to swallow the compound; * stable concomitant medications for at least 2 weeks (4 weeks if patient took fluoxetine); * no planned changes in psychosocial interventions during the open-label trial. exclusion criteria: * dsm-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified; * prior adequate trial of esomeprazole; * active medical problems such as unstable seizures, or significant physical illness (e.g., serious liver or renal pathology).

Keywords: esomeprazole
home sleep and metabolism

Conditions: Overweight; Sleep

Summary: bedtimes and wake-up times vary from person to person. the aim of this research is to examine the associations between sleep habits and metabolism in healthy people. in this study, the investigators will collect information on sleep-wake habits and how the body uses energy.


Eligibility criteria:
inclusion criteria: * age: 21-40 years * body mass index: 25.0 to 29.9 kg/m2 * average habitual sleep duration of 6.5 hours or less per night (as confirmed by actigraphy) * stable sleep habits for the past 6 months exclusion criteria: * obstructive sleep apnea or history of any other sleep disorder * night or rotating shift work (current or in the past 2 years) * habitual daytime naps * recent (\< 4 week) travel across time zones * extreme chronotypes * any acute or chronic medical condition * diabetes * prior or current eating or psychiatric disorders * claustrophobia * irregular menstrual periods, menopause, pregnancy, * alcohol abuse, excessive caffeine intake, smoking, illegal drug use * subjects who are currently following a weight loss regimen or any other special diet or exercise programs * subjects who have received iv or oral contrast in the past 2 weeks * use of any prescription medication that can affect sleep or metabolism with the exception of antihypertensive and lipid lowering agents as follows. subjects who are taking anti-hypertensive medication and/or lipid-lowering agents will be included only if they are well controlled and on a stable regimen (no change in medications in the previous 3 months). however, beta-blockers and thiazide diuretics will not be allowed, as these medications are known to affect insulin sensitivity. women will be required to not be on hormone replacement therapy.